Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
A Phase I/II Clinical Trial of Topical KB105, a Replication-incompetent, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
Sponsor: Krystal Biotech, Inc.
This PHASE1/PHASE2 trial investigates TGM-1 Related Autosomal Recessive Congenital Ichthyosis and is currently ongoing. Krystal Biotech, Inc. leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Apr 2025 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 1 earlier version
-
Sep 2019 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Krystal Biotech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .